Company intelligence / Profile preview
Cascade Biotechnology
Pennington, NJ, United Statescascadebiotechnology.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
No clinical results reported yet. Most programs are at early discovery or preclinical/in vitro research stages. The lead technology involves stabilized C3 analogs with improved potency/stability over existing agents like cobra venom factor.
- Therapeutic areas
- NeurologyPsychiatryOphthalmologyHematologyNephrologyImmunologyCardiovascular
- Modalities
- ProteinGene therapyConjugate-based delivery systems
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships disclosed publicly as of June 2025.
Beyond the preview
Go deeper on Cascade Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cascade Biotechnology.